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Abstract
The function of EED within Polycomb repressive complex 2 (PRC2) is mediated by a complex 
network of protein-protein interactions. Allosteric activation of PRC2 by binding of methylated 
proteins to embryonic ectoderm development (EED) aromatic cage is essential for full catalytic 
activity, but details of this regulation are not fully understood. EED’s recognition of the product of 
PRC2 activity, histone H3 lysine 27 trimethylation (H3K27me3), stimulates PRC2 
methyltransferase activity at adjacent nucleosomes leading to H3K27me3 propagation and, 
ultimately, gene repression. By coupling combinatorial chemistry and structure-based design, we 
optimized a low affinity methylated jumonji, AT rich interactive domain 2 (Jarid2) peptide to a 
smaller, more potent peptidomimetic ligand (Kd = 1.14 ± 0.14 μM) of the aromatic cage of EED. 
Our strategy illustrates the effectiveness of applying combinatorial chemistry to achieve both 
ligand potency and property optimization. Furthermore, the resulting ligands, UNC5114 and 
UNC5115, demonstrate that targeted disruption of EED’s reader function can lead to allosteric 
inhibition of PRC2 catalytic activity.
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INTRODUCTION
PRC2 is a multisubunit protein complex controlling cellular fate decisions through 
epigenetic transcriptional repression of key genes involved in development. The fundamental 
role of PRC2 deposition of the repressive chromatin mark, H3K27me3, promoted extensive 
characterization of the PRC2 core complex, consisting of enhancer of zeste homolog 1/2 
(Ezh1/2) (the methyltransferase catalytic subunit), suppressor of zeste 12 (Suz12), and 
EED1–4. As a central mediator of gene repression, PRC2 functions are both diverse and 
essential, but the complexity of PRC2 biology has prevented the establishment of a 
straightforward and comprehensive model for its actions5–7. Recent efforts have led to new 
insights into PRC2 regulation of chromatin structure and gene repression along with 
indications of PRC2 misregulation in disease, particularly in cases of hematopoietic cancers8 
and pediatric glioma9. The discovery of potent, in vivo chemical probes of Ezh1/210–13 have 
aided in validating Ezh2 as a druggable component of PRC2, and encouragingly, Ezh2 
inhibitors have since entered clinical trials14. New chemical tools to study other components 
of PRC2 may similarly provide a path to an improved understanding of its regulation, 
function, and therapeutic potential.
While a complete mechanistic understanding of PRC2 function remains elusive, several 
research groups have characterized the allosteric regulation of PRC2 activity facilitated by 
EED. Similar to many WD40 proteins, EED serves as a scaffold for protein complex 
assembly15. EED’s indispensable role in PRC2 involves an intricate network of protein-
protein interactions with both Ezh2 and Suz12, as Ezh2’s catalytic activity is entirely 
dependent on PRC2 core complex formation3–4. EED associates with the product of PRC2 
activity, H3K27me3, and EED binding to H3K27me3 stimulates PRC2 to methylate 
adjacent nucleosomes leading to H3K27me3 propagation over large genomic loci and gene 
repression16. EED has also been shown to interact with inhibitory histone marks (histone H1 
lysine 26 trimethylation)17, but the biological significance of this mark for EED regulation 
has been poorly studied.
Recently, Jarid2 trimethylated at lysine 116 (Jarid2-K116me3) was described as an EED 
binding partner and allosteric activator of PRC2 methyltransferase activity18. The regulation 
of PRC2 through EED binding to both H3K27me3 and Jarid2-K116me3 illustrates the 
difficulty in developing a comprehensive model for PRC2 regulation. Moreover, the 
methylated Jarid2 peptide demonstrates 10-fold higher affinity for EED in vitro than 
H3K27me3 (3.4 vs 40 μM).
The recently solved crystal structures of the three core components of PRC2 are noteworthy 
achievements, and importantly provide a clear model for the allosteric activation of Ezh2’s 
methyltransferase activity by EED15,19,20. Engagement of the aromatic cage and top surface 
of EED by methylated Jarid2-K116me3 (or H3K27me3)15 stimulates the folding of an 
unstructured region of Ezh2 into an alpha helix, denoted as the stimulation response motif 
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(SRM). This helix in turn stabilizes the SET-I helix which forms part of the substrate 
binding site of the Ezh2 SET domain. Overall, these results suggest that EED ligands may 
either act as positive allosteric modulators of Ezh2, if they fully mimic natural ligands and 
aid in folding the SRM helix, or potentially act as inhibitors if they: bind and do not stabilize 
the SRM helix, thereby blocking allosteric activation by endogenous EED ligands (neutral 
allosteric interaction); or bind and also disrupt substrate binding in the orthosteric, catalytic 
site (negative allosteric modulators).21
There is a growing interest in targeting chromatin-modifying enzymes with small molecules, 
and inhibitors for methyl-lysine (Kme) readers are similarly desirable as tools to elucidate 
the role of these readers in chromatin dysregulation and disease22–23. However, targeting the 
surface-groove binding mode of most Kme readers remains challenging, an issue 
exemplified by the dearth of chemical tools for studying Kme reader function. Currently, 
only two chemical probes of Kme readers have been published, while seven additional 
targets have literature on ligand development but lack adequate characterization, affinity, or 
cellular efficacy to be considered probes24–31. Of the two successful chemical probes, the 
discovery of a peptide-derived chemical probe, UNC3866, for the Polycomb repressive 
complex 1 (PRC1) chromodomain Kme3 readers has demonstrated the potential for 
selectively targeting these readers via cell permeable peptide mimetics32. Utilizing peptides 
as a foundation for inhibitor discovery offers several advantages including a rational starting 
point based on the native ligand. Additionally, our recent development of a combinatorial 
peptide platform to target Kme reader proteins enables rapid peptide optimization24. Such a 
combinatorial strategy for inhibitor discovery bypasses many of the drawbacks of a more 
traditional medicinal chemistry approach, namely cost, synthetic effort, and possible missed 
synergistic effects. Furthermore, compound libraries can be designed to improve ligand 
properties and competitor exchange kinetics can be applied to isolate ligands of equal or 
better potency. Thus, peptide ligand optimization provides an efficient and cost effective 
strategy for developing new chemical tools to study EED biology.
We present an in vitro chemical toolkit to study the role of EED’s Kme reader function in 
the context of PRC2 activity. The pairing of combinatorial chemistry and structure-based 
design provides a platform for rapid optimization of ligand potency and chemical properties. 
This strategy enabled us to optimize the 12-mer Jarid2-K116me3 peptide to the 4-mer 
UNC5114, a 1 μM EED binder. A biotinylated derivative effectively chemiprecipitated the 
core PRC2 components, EED, Suz12, and Ezh2, from cell lysates. Finally, we demonstrate 
that the targeted disruption of EED’s reader function allosterically inhibits PRC2 catalytic 
activity. (While this manuscript was in revision a study reporting EED directed PRC2 
inhibitors developed from an HTS hit appeared.33)
METHODS
EED expression and purification (Library screening, ITC, FP assays)
The chromodomain of CBX7 (residues 8–65 of NP_055107) was expressed and purified as 
previously described32. Full length EED (reference sequence AAD08714) was expressed 
with an N-terminal His-tag in a pET28 vector. The pET28-EED expression construct was 
transformed into Rosetta2 BL21(DE3)pLysS competent cells (Novagen, EMD Chemicals, 
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San Diego, CA). Protein expression was induced by growing cells at 37°C with shaking until 
the OD600 reached ~0.6–0.8 at which time the temperature was lowered to 15°C and 
expression was induced by adding 0.1mM IPTG and continuing shaking overnight. Cells 
were harvested by centrifugation and pellets were stored at −80°C.
His-tagged EED protein was purified by resuspending thawed cell pellets in 30ml of lysis 
buffer (50mM sodium phosphate pH 7.2, 150mM NaCl, 30mM imidazole, 1X EDTA free 
protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN)) per liter of culture. Cells 
were lysed on ice by sonication with a Branson Digital 450 Sonifier (Branson Ultrasonics, 
Danbury, CT) at 40% amplitude for 12 cycles with each cycle consisting of a 20 second 
pulse followed by a 40 second rest. The cell lysate was clarified by centrifugation and 
loaded onto a HisTrap FF column (GE Healthcare, Piscataway, NJ) that had been pre-
equilibrated with 10 column volumes of binding buffer (50mM sodium phosphate pH 7.2, 
500mM NaCl, 30mM imidazole) using an AKTA FPLC (GE Healthcare, Piscataway, NJ). 
The column was washed with 15 column volumes of binding buffer and protein was eluted 
in a linear gradient to 100% elution buffer (50mM sodium phosphate pH 7.2, 500mM NaCl, 
500mM imidazole) over 20 column volumes. Peak EED containing fractions were pooled 
and concentrated to less than 8ml in Amicon Ultra-15 concentrators 10kDa molecular 
weight cut-off (Merck Millipore, Carrigtwohill Co. Cork IRL). Concentrated protein was 
loaded onto a HiLoad 26/60 Superdex 200 prep grade column (GE Healthcare, Piscataway, 
NJ) that had been preequilibrated with 1.2 column volumes of sizing buffer (25mM Tris pH 
7.5, 500mM NaCl, 2mM DTT, 5% glycerol) using an ATKA FPLC (GE Healthcare, 
Piscataway, NJ). Protein was eluted isocratically in sizing buffer over 1.3 column volumes at 
a flow rate of 2ml/min collecting 3ml fractions. Peak fractions were analyzed for purity by 
SDS-PAGE and those containing pure protein were pooled and concentrated using Amicon 
Ultra-15 concentrators 10kDa molecular weight cut-off (Merck Millipore, Carrigtwohill Co. 
Cork IRL). Concentrated EED protein was dialyzed into a buffer containing 25mM Tris, pH 
7.5, 250mM NaCl, 2mM DTT, 5% glycerol for storage.
Library Screening
For the first generation library, one-tenth of the synthesized library was removed to a 2 mL 
Eppendorf tube and equilibrated in 25 mM Tris, pH 7.8, 150 mM NaCl, and 0.1% Tween-20 
(TBST) overnight. All incubation steps were conducted at room temperature. Individual 
magnetic screens follow a similar protocol to that originally described by Astle et al2. For 1 
hour, the beads were blocked in 5% BSA in TBST (1.8 mL). The resin was washed three 
times in TBST (1.8 mL) followed by addition of 1 μM His-tagged CBX7 (His6X-CBX7) in 
2.5% BSA in TBST (1.8 mL) for 1 hour. Protein G Dynabeads (10 μL; Life Technologies) 
were loaded with mouse anti-His antibody (2 μL of a 1 μg/μL solution; Pierce MA1-21315) 
concurrently (1 hour). Excess antibody was removed and the Dynabeads were washed 3 
times with TBST (200 μL), and the library was also washed 3 times with TBST (1.8 mL). A 
solution of the anti-His antibody loaded Dynabeads in 2.5% BSA in TBST (1.5 mL) was 
added to the library, and the library beads and magnetic beads were left to rotate for hour. A 
magnet was used to separate CBX7 hits and nonspecific binders from the remaining library. 
To prepare for the subsequent EED screen, the remaining library was stripped with 1% SDS 
(1.8 mL) at 95°C for 3 minutes. The library was then rinsed with 0.1% Tween-20, 1M 
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sodium chloride, and three times with TBST. The library was rotated in TBST overnight at 
4°C. The next day 1 μM His6X-EED was screened as described above except magnetized 
hits from this screen were isolated and saved in a 0.6 mL Eppendorf tube. Hit PEGA beads 
were left to settle at the bottom of the tube while excess magnetic beads were removed by 
pulling off the solution by pipette. A solution of 10 μM Jarid2114–118K116me3 in 2.5% BSA 
in TBST (500 μM) was added to the hit beads. The hits were left to rotate in this solution for 
2 hours, and the beads were subjected to a magnet and unmagnetized beads were removed to 
a separate Eppendorf tube. The hit beads that remained magnetized throughout the soluble 
competitor treatment were stripped with 1% SDS at 95°C for 3 minutes then rinsed 
repeatedly with TBST followed by 0.1% Tween-20 and finally rinsed and equilibrated 
overnight in ethanol.
The second generation library also employed a negative selection (His6X-CBX7) and target 
screening (His6X-EED) as described above, except 20 μL Protein G Dynabeads was used 
with 4 μL of anti-His antibody. Compound 2 was used as the soluble competitor.
FP Assays
Binding assays were carried out in buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, 
and 1mM CHAPS in black 384-well microplates (Greiner) with total reaction volumes of 25 
μL. To each well, 15 μL of buffer was added followed by the addition of 5 μL of a 2.000, 
1.000, 0.500, 0.250, and 0.125 μM compound 3-FAM. Serial dilutions of His6x-EED were 
prepared and 5 μL was added to give final protein concentrations ranging from 0–50 μM. 
After 30 minutes at room temperature, FP measurements were taken on an AcQuest (LJL 
BioSystems) plate reader, with an excitation wavelength of 485 nm and the emission 
collected at 530 nm. This 2D titration was run in duplicate and led to the selection of 50 nM 
of compound 3-FAM and 1.5 μM of His6xEED as concentrations for follow-up 
displacement assays since. This combination was selected due to approximately 80% 
saturation of EED binding sites and a significant signal-to-noise window.
Displacement assays were conducted similarly, but with the following changes. First, 10 μL 
of buffer was added before addition of 5 μL of 0.250 compound 3-FAM and 5 μL of 7.5 μM 
His6x-EED. After 30 minutes, 5 μL from serial dilutions (0–100 μM) of each compound 
were added to the wells. The plate was left to incubate at room temperature for an additional 
30 minutes and then read. Each reaction was run in triplicate or quadruplicate.
ITC Experiments
ITC measurements were recorded at 25°C using an AutoITC200 microcalorimeter 
(MicroCal Inc., MA). Protein stocks were prepared in ITC buffer (25 mM Tris-HCl, pH 8, 
250 mM NaCl, and 2 mM β-mercaptoethanol) and then diluted into ITC buffer to achieve a 
final concentration of 50 μM (325 μL). All compounds were dissolved in water to a stock 
concentration of 10 mM and then diluted to a final concentration of 500 μM. A typical 
experiment included a single 0.2 μl compound injection into a 200 μl cell filled with protein, 
followed by 26 subsequent 1.5 μl injections of compound. Injections were performed with a 
spacing of 180 s and a reference power of 8 μcal/s. The titration data was analyzed using 
Origin Software (MicroCal Inc., USA) by nonlinear least-squares, fitting the heats of 
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binding as a function of the compound:protein ratio to a one site binding model. The first 
data point was deleted from all analyses.
PRC2 Complex Expression and Purification
DNA fragments encoding the genes of the full lengths of two components of PRC2 complex, 
EED(1–441) and EZH2(1–751) were cloned into pFastBac-Dual (Invitrogen) and the full 
length of SUZ12(1–739) were cloned into pFastBac HT A (Invitrogen). The resulting 
plasmids were transformed into DH10Bac™ Competent E. coli (Invitrogen) and the 
recombinant viral DNA bacmids were purified and followed by a recombinant baculovirus 
generation in Sf9 insect cells. Sf9 cells grown in HyQ®SFX insect serum-free medium 
(ThermoScientific) were co- infected with 10 ml of each P3 viral stocks per 0.8 L of 
suspension cell culture and incubated at 27°C using a platform shaker set at 100 RPM. The 
cells were collected after 72 hours of post infection time, when viability dropped to 70–80%. 
Harvested cells were re-suspended in PBS, 1X protease inhibitor cocktail (2.5 μg/ml 
Aprotinin, 2.5 μg/ml Leupeptin, 2.5 μg/ml Pepstatin A and 2.5 μg/ml E-64) or a complete 
EDTA-free protease inhibitor cocktail tablet (Roche). The cells were lysed chemically by 
rotating 30 min with NP-40 (final concentration of 0.6%) and 50 U/mL Benzonase nuclease 
(Sigma) and 2 mM 2-mercaptoethanol followed by sonication at frequency of 8 (10 sec 
on/10 sec off) for 4 min (Sonicator 3000, Misoni). The crude extract was clarified by high-
speed centrifugation (60 min at 36,000 ×g at 4°C) in a Beckman Coulter centrifuge. The 
recombinant protein complex was purified by incubating the cleared lysate with equilibrated 
Anti-FLAG M2 Affinity agarose gel (Sigma, Cat # A2220) for 1.5 hours with rotating, 
followed by washing with 10 column volumes of TBS (50 mM Tris-HCl, with 150 mM 
NaCl, pH 7.4). The recombinant protein complex was eluted by competitive elution with 
100 μg/ml FLAG peptide (Sigma, Catalog # F4799) in TBS and 5% glycerol. Purity was 
judged by SDS–PAGE and the protein was subsequently concentrated and flash frozen. 
Aromatic cage mutations of EED in this PRC2 construct were also created by site-directed 
mutagenesis as described for the EED single constructs. PRC2 complexes containing these 
EED mutations were expressed and purified as the wildtype.
PRC2 Methyltransferase Activity Assay
Methyltransferase activity assays for EZH2 trimeric complex (EZH2:EED:SUZ12) were 
performed by monitoring the incorporation of tritium-labeled methyl group to lysine 27 of 
H3 (21–44) peptide using Scintillation Proximity Assay (SPA). The enzymatic reactions 
were performed at 23 °C with 1 hour incubation of 10 μl reaction mixture in 20 mM Tris-
HCl, pH 8, 5 mM DTT, and 0.01% Triton X-100 containing 1 μM of 3H-SAM (Cat.# 
NET155V250UC; Perkin Elmer; www.perkinelmer.com), 1 μM of biotinylated H3 (21–44), 
20 nM EZH2 complex, and compound titration from 50 μM to 50 μM. To stop the reactions, 
10 μL of 7.5 M Guanidine hydrochloride was added, followed by 200 Gl of buffer (20 mM 
Tris, pH 8.0), mixed and transferred to a 96-well Streptavidin coated Flash-plate 
(PerkinElmer,http://www.perkinelmer.ca). After mixing, Flash-plates were incubated for 2 
hour and the CPM counts were measured using Topcount plate reader (Perkin Elmer, 
www.perkinelmer.com). The CPM counts in the absence of compound for each dataset were 
defined as 100% activity. In the absence of the enzyme, the CPM counts in each data set 
were defined as background (0%). All enzymatic reactions were performed in triplicate and 
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IC50 values were determined by fitting the data to Four Parameter Logistic equation using 
GraphPad Prism 7 software.
For competition experiments with H3K27me3 peptide, 0, 1 or 10 μM H3K27me3 (19–33) 
peptide were included in the reaction mixture. For data sets involving comparison of the 
wildtype complex activity against those of the mutants, the CPM counts of the wildtype 
complex in the absence of compound were defined as 100% activity. In the absence of the 
enzyme, the CPM counts in each data set were defined as background (0%). The enzymatic 
reactions were performed in triplicate and IC50 values were determined by fitting the data to 
Four-Parameter Logistic equation using SigmaPlot version 11.0.
Additional methods, including compound synthesis and characterization, crystallography, 
and pull-down experiments, are described in the Supporting Information.
RESULTS AND DISCUSSION
The recent characterization of EED’s binding to methylated Jarid2 at low micromolar 
potency (Jarid2110–120-K116me3, Kd ~ 3 μM)18 provided a rational starting point for peptide 
optimization to target the reader interface of EED. We initially set out to design and test the 
affinity of a truncated Jarid2-K116me3 peptide. By analyzing the co-crystal structure of 
Jarid2-K116me3 and EED (PDB 4X3E) we noted that the majority of specific protein-
protein contacts were largely confined to five residues within Jarid2 (Jarid2114–118K116me3, 
Figure 1a). Distinctively, the glutamine 114 side chain rests in a small hydrophobic pocket 
while the backbone carbonyl appears to make a hydrogen bond with tryptophan 364 of the 
EED aromatic cage. K116me3 binds in the aromatic cage while its carbonyl and that of the 
adjacent arginine 115 form additional hydrogen bonds with EED. Unlike the H3K27 
sequence, Jarid2114–118K116me3 contains a phenylalanine at the +1 position adjacent to the 
methylated lysine. Phenylalanine 117 was shown to be essential for Jarid2 binding and the 
crystal structure demonstrates that the aromatic ring is positioned to either stack with 
phenylalanine 97 of the aromatic cage or to further enclose K116me3 within the cage. 
Lastly, alanine 118 of Jarid2 binds in a shallow hydrophobic patch on EED’s surface. We 
synthesized Jarid2114–118K116me3 and tested its affinity for EED by isothermal titration 
calorimetry (ITC) (Kd = 8.82 ± 2.06 μM; Supplementary Information Figure S1). The 
truncated peptide demonstrated less than a 3-fold loss in affinity compared to the published 
value for Jarid2110–120-K116me3, confirming that the bulk of EED’s affinity for Jarid2-
K116me3 is due to contacts with these five residues.
To confirm EED’s compatibility with our on-bead, magnetic enrichment screening approach 
(Figure 1b), Jarid2114–121-K116me3 was synthesized on PEGA resin (Jarid2114–121-
K116me3-PEGA) as a control ligand24,34. Histone peptides, with their high charge density 
and numerous arginines, lysines and glutamines, interact non-specifically with the 
components of the on-bead assay. The longer Jarid2 peptide seemed likely to face similar 
issues, which led us to select a truncated Jarid2 peptide sequence for on-bead screen 
development. Though the longer peptide is unnecessary for maintaining affinity to EED, the 
additional residues serve as a spacer between the methionine required for cyanogen bromide 
(CNBr) cleavage and the protein-binding region of the peptide. Following our previous Kme 
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reader screening protocol24, His-tagged EED (His6X-EED) was incubated with bovine 
serum albumin-blocked Jarid2114–121-K116me3-PEGA. Simultaneously, mouse anti-His6X 
antibody was bound to magnetic Protein G Dynabeads. Following extensive washing, the 
antibody-coated Dynabeads were added to the preincubated Jarid2114–121-K116me3-PEGA 
resin. Jarid2114–121-K116me3-PEGA became selectively magnetized only in the presence of 
His6X-EED, as expected. In contrast, UNC3866-PEGA failed to become magnetized in 
either the presence or absence of His6X-EED which recapitulated EED’s lack of affinity for 
UNC3866 in solution-based assays32 and helped to confirm that successful magnetization 
occurs only in the presence of genuine EED ligands.
Having established the peptide region of Jarid2 that we planned to optimize and validated 
EED in our magnetic enrichment assay, we began designing a first generation combinatorial 
library of potential EED ligands (Figure 1c). Our initial library design focused on improving 
the undesirable properties of Jarid2114–118K116me3, namely the presence of a primary 
amine at the N-terminus, a quaternary amine, a guanidinyl group, and an overall +3 charge 
state. Our library tested a variety of carboxylic acid caps at the N-terminus as replacements 
for glutamine 114, while also including an acetyl-capped glutamine in case this residue was 
required for EED activity. Previous studies indicated that an arginine at the −1 position of 
Kme3 was essential for stimulation of PRC2 catalytic activity though unnecessary for 
binding to EED16–17. Potential arginine replacements in our library included serine and 
alanine, for example, as well as riskier substitutions including peptoid residues in an attempt 
to reduce the number of backbone hydrogen bond donors. A variety of natural and unnatural 
aromatic residues were tested in place of Phe at the R4 position, while only modest changes 
were included at the Kme3 position.
Using split-and-pool synthesis35, the 1,029 compound library was synthesized at 
approximately 20-fold redundancy (Figure 1c). To diminish the resynthesis of false positives 
we included multiple copies of each potential ligand in the library so that hits could be 
prioritized by redundancy for follow-up studies36. Kme derivatives were synthesized via 
reductive amination with lysine to form the tertiary amines followed by substitution to yield 
the desired quaternary amines. Incorporation of methionine as the first residue of the linker 
enabled cyanogen bromide (CNBr) cleavage from the resin for hit deconvolution by MALDI 
MS/MS. Amino acids were added via standard Fmoc solid phase synthesis while peptoids 
were synthesized by bromoacetic acid coupling and then substitution with a primary amine. 
Deprotection of the pooled library to remove Boc/tBu groups was conducted under acidic 
conditions, and then the final library was equilibrated in aqueous buffer prior to screening.
A preliminary negative selection of the library was conducted with the chromodomain of 
CBX7, a Kme reader also known to bind H3K27me3. Magnetized beads were presumed to 
either bind nonspecifically to the components of the assay (Protein G Dynabeads and anti-
His6x antibody) or specifically to CBX7. Magnetized beads were removed from the library 
while the unmagnetized beads were carried forward, and His6X-EED was then screened 
against the remaining library. Magnetically isolated EED hit beads were separated and 
treated with a soluble competitor ligand, Jarid2114–118K116me3 (10 μM), to elute off low 
affinity hits and retain only those ligands with improved potency over the truncated Jarid2 
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peptide. After 120 minutes, those hits that remained magnetized were isolated, stripped, and 
cleaved from the bead with CNBr before being sequenced by tandem mass spectrometry.
Two hits were isolated with a greater than 2-fold redundancy (Figure 1d; Supplementary 
Information Figure S2), both of which included cyclohexane carboxylic acid as a glutamine 
replacement at the N-terminus. At positions R4 and R3, respectively, phenylalanine and 
Kme3 residues were conserved, but the hits varied at the R2 position containing either a 
lysine or serine. After resynthesis of compound 1, hit confirmation by ITC demonstrated a 
slight improvement in potency relative to Jarid2114–118K116me3 (compound 1: Kd = 4.74 
± 0.69 μM vs Jarid2114–118K116me3: Kd = 8.82 ± 2.06 μM; Supplementary Information 
Figure S1). In addition to replacing the N-terminal amine and the glutamine side chain 
primary amide, both ligands also revealed suitable replacements for the guanidinyl group of 
arginine. Overall, this first generation EED-targeted library resulted in improved ligand 
potency and physicochemical properties while important insights were gained into the 
amenability of replacing the two N-terminal residues.
We next designed a larger second generation library consisting of 4,410 compounds taking 
into account insights from our initial screening results (Figure 2). The goal of this library 
was primarily to improve ligand affinity so both conservative and riskier modifications were 
tested at positions R1, R2, R4, and R5 while only Kme3 was incorporated at position R3. 
For instance, several phenylalanine derivatives were included at position R4 to potentially 
improve the interaction of the ring with the aromatic cage or the Kme3 side chain. We 
included a deeper exploration of cyclic analogs at the N-terminal capping position based on 
conservation of the cyclohexyl cap in both hits of the first generation library. Additionally, 
while the C-terminal alanine was not altered in the previous library, a variety of residues 
with small hydrophobic side chains were included in the second generation library to probe 
a small hydrophobic patch on EED’s surface. Additionally, the second generation library 
included a modified linker. Firstly, an alkyne was included because previous studies37–38 had 
applied this strategy to derivatize ligands after bead cleavage, though our approach in this 
study did not employ this group. Secondly, alanine and beta-alanine were included in the 
linker to provide space between the compound and the methionine and the alkyne. Since this 
library sought only to probe the affinity of the 5-mer peptide, the native sequence was not 
used as the linker to avoid any effects this sequence might have on affinity.
Screening followed an identical protocol as described above with the substitution of 
compound 2 as the soluble competitor. Nine ligands with a redundancy greater than 2-fold 
were isolated, and a number of structural similarities were observed (a subset are shown in 
Supplementary Information Figure S3). The capping residue (R1) favored aliphatic 
heterocycles while significant tolerance was found at the R2 position. Although two hits 
with 3-fluorophenylalanine at R4 were identified, retention of phenylalanine was clearly 
preferred. Lastly, the R5 position favored either leucine or valine suggesting that increased 
hydrophobic contacts at the C-terminus improve the interaction between the peptide and 
EED. Based on these hit structures, we synthesized a peptide combining the residues that 
appeared most frequently (compound 3; Kd = 1.09 ± 0.27 μM; Supplementary Information 
Figure S1) which resulted in an approximately 4-fold enhancement in affinity compared to 
compound 1 (Figure 3a). By applying combinatorial optimization to Jarid2114–118K116me3, 
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only two iterations of library design and screening reduced the overall ligand charge from +3 
to +2 and produced a 10-fold improvement in potency.
We next solved the co-crystal structure of compound 3 bound to EED (Figure 3b, (PDB 
5TTW)). Unsurprisingly, the Kme3 and phenylalanine residues adopt an identical binding 
mode to Jarid2K116me3 (PDB 4X3E). Interestingly, the C-terminus binds in a unique 
orientation that positions the hydrophobic leucine side group toward EED’s surface (Figure 
3c,d). The isoleucine 363 side chain and the carbon chain of glutamine 382 form van der 
Waal contacts with the leucine side chain of 3 while the backbone primary amide does not 
interact with EED. Although the amide bond between phenylalanine and leucine in 
compound 3 does not appear to make specific hydrogen bond contacts, the carbonyls of 
lysine and serine form hydrogen bonds with residues at the base of EED’s aromatic cage. 
Additionally, while the serine backbone seems critical for bridging the methylated lysine 
within the aromatic cage and the proline that interacts with a small hydrophobic pocket 
formed by asparagine 307, tyrosine 308, and cysteine 324, the side chain of serine has no 
apparent interactions, suggesting this group is non-essential for binding. This is consistent 
with the variability observed at this position in both libraries. Overall, the co-crystal 
structure strongly implicated the potential for replacing the leucine of compound 3 with a 
non-peptidic, hydrophobic group and replacement of the proline-serine N-terminus.
In the next phase of optimization, we C-terminally labeled compound 3 with fluorescein to 
enable an EED fluorescence polarization (FP) assay (Supplementary Information Figure 
S4a). Following optimization of protein and fluorescent ligand concentrations 
(Supplementary Information Figure S4b), we validated this assay by displacing the bait 
peptide with compound 3, and an IC50 (1.65 ± 0.66 μM) approximately the same as the Kd 
(1.09 ± 0.27 μM) was observed (Table 1; curves shown in Supplementary Information 
Figure S5). Similarly, Jarid2114–118K116me3 demonstrated an IC50 (14.78 ± 2.24 μM) on 
par with its measured Kd (8.82 ± 2.06 μM) so we moved forward by testing new compounds 
via FP followed by ITC characterization for the most promising ligands.
Subsequent compound optimization focused on modifying the two termini to reduce the 
length of the peptide and replacing the quaternary amine. Initially, the C-terminal leucine 
was replaced by a piperidinyl ring (compound 4). This substitution had minimal effects on 
potency indicating that the piperidine ring could mimic important hydrophobic contacts 
made by the leucine side chain while both the C-terminal amide and the backbone amide 
proton of the leucine residue were not required for EED binding. Next, since quaternary 
amines are suggested to prevent passive diffusion through the lipid bilayer, the trimethyl 
substitution on the lysine was replaced by various tertiary amines including diethyl (5), 
methyl-cyclohexyl (6), and methyl-isopropyl (7). When compared to Kme3, the 
corresponding methyl-cyclohexyl ligand lost nearly all binding to EED (IC50> 30 μM) 
whereas the diethyl-lysine-containing ligand resulted in a 7-fold reduction in potency. 
Methyl-isopropyl was found to be the best substitute for Kme3 with only a 3-fold loss in 
affinity. Following selection of methyl-isopropyl lysine (Kme,iPr) for further optimization, 
three bicyclic capping residues were tested to replace the proline-serine N-terminus. While 
two of the capping residues containing aromatic rings to potentially stack with tryptophan 
364 or tyrosine 308 did not potently interact with EED (compounds 8 and 9), an (2S,3aS,
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7aS)-octahydro-1H-indole cap (compound 10, UNC5114) not only maintained EED affinity 
but even compensated for the slight loss in potency due to the Kme,iPr substitution. 
Incorporating the C-terminal piperidinyl ring into UNC5114 (compound 11, UNC5115) 
resulted in a 2-fold loss in potency relative to UNC5114. Follow-up ITC experiments 
confirmed UNC5114 (Kd = 0.68 ± 0.05) and UNC5115 (Kd = 1.14 ± 0.14) potencies. 
Additionally, we speculated that methylation of the phenylalanine amide in UNC5115 would 
disrupt the ability of the phenyl ring to fold over the aromatic cage and the lysine side chain, 
thus abolishing EED binding. UNC5197 (Figure 4a) ITC data confirmed that this 
methylation disrupts binding and hence this compound represents an ideal negative control 
for subsequent studies. Overall, UNC5114 contains only three hydrogen bond donors and a 
+2 charge state which is a dramatic improvement over the 5-mer Jarid2114–118K116me3 
ligand that includes nine hydrogen bond donors and a +3 charge state.
Having discovered of a set of peptide-competitive chemical tools with low micromolar to 
high nanomolar in vitro affinities for EED, we next sought to investigate how targeted 
disruption of the PRC2 reader function would alter catalytic activity of the complex. 
Although previous studies have demonstrated allosteric activation of PRC2 catalytic activity 
by several methylated peptides, we hypothesized that our ligands would not be stimulatory 
because they lack the requisite arginine at the −1 position to Kme3 that is required for 
stabilization of the SRM helix. We moved forward by characterizing the effects of 
compound 3, UNC5114, and UNC5115 in a PRC2 methyltransferase scintillation proximity 
assay12 (Figure 4b). In brief, this assay monitors the transfer of a tritiated methyl group from 
the cofactor S-adenosyl methionine to a histone H321–44K27 unmodified peptide. 
Interestingly, all three ligands inhibit catalytic activity, albeit to only about 80% at saturating 
concentrations of ligand. We believe this residual 20% activity may correspond to a basal 
activity of the unstimulated Ezh2 enzyme within the PRC2 core complex, as direct inhibition 
of Ezh2 catalytic domain with SAM-competitive inhibitors completely eliminates enzyme 
activity10,11,12,13.
To biochemically probe the allosteric inhibition of PRC2 via binding to the EED reader 
pocket, UNC5114 and UNC5115 were incubated with the PRC2 core complex in the 
presence or absence of the stimulatory H3K27me3 peptide. Increasing concentrations of the 
H3K27me3 peptide increased the activity of the enzyme but also increased the apparent IC50 
values of both compounds (Figure 5). These results are consistent with a mechanism of 
action in which the compounds inhibit PRC2 by competing with the stimulatory peptide, 
thereby preventing allosteric stimulation of the enzyme. EED aromatic cage mutants (F97A, 
W364A, and Y365A) were also generated to further test this mechanism of PRC2 inhibition. 
Differential static light scattering (DSLS) confirmed that all three mutants demonstrated a 
similar thermal aggregation stability profile to wild-type EED, suggesting that these mutants 
are properly folded (Supporting Information Figure S6). When reconstituted into a core 
PRC2 complex, the EED mutants exhibit significantly lower levels of basal catalytic activity, 
and UNC5114 and UNC5115 clearly fail to inhibit this activity whereas the EZH2 chemical 
probe UNC1999 completely abrogates the activity (Supporting Information Figure S7), 
similar to its inhibition of wildtype PRC2. Taken together, these results demonstrate that 
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UNC5114 and UNC5115 act as allosteric inhibitors of PRC2 methyltransferase activity 
through competitive inhibition of the EED Kme reader function.
In order to confirm that UNC5114 and UNC5115 are able to target native PRC2 from cells, 
we biotinylated UNC5114 to attempt chemiprecipitation of PRC2 components from cellular 
lysates (Figure 6a). Streptavidin coated magnetic Dynabeads were incubated with 
biotinylated UNC5114 followed by the addition of PC-3 cell lysates in the presence and 
absence of soluble UNC5114 to confirm the specificity of the pulldown. Western blot 
analysis indicated successful pulldown of all three core components of PRC2: EED, Ezh2, 
and Suz12 (Figure 6b). These results confirm that biotin-UNC5114 engages the Kme reader 
pocket of EED without disrupting assembly of the PRC2 complex and that our ligands bind 
endogenous EED.
CONCLUSIONS
A paired combinatorial and structure-based optimization strategy led to the discovery of two 
small, peptidomimetic ligands of EED. These ligands exhibit improved potency (~10-fold) 
and physicochemical properties compared to Jarid2114–118K116me3, and they demonstrate 
the feasibility of optimizing a peptidic antagonist of a Kme reader domain for targeted 
disruption of its reader function. Moreover, compound 3 could be easily functionalized to 
facilitate the development of an FP assay, and UNC5114-biotin enabled chemiprecipitation 
experiments that show maintenance of affinity for endogenous EED. Most interestingly, the 
disruption of PRC2 catalytic activity by UNC5114 and UNC5115 presents a unique 
opportunity to probe allosteric regulation of H3K27me3 deposition particularly when 
considering that the allosteric mechanisms governing PRC2 are only beginning to be 
understood. It is possible that, in addition to competitively preventing allosteric activation, 
these peptidomimetic EED ligands disrupt catalytic activity by preventing the stabilization 
and orientation of the stimulation response motif (SRM) helix of EZH2 as described by Jiao 
and Liu15 (Figure 7). Consequently, the SRM helix cannot in turn stabilize the SET-I helix 
which contributes many of the residues that interact with the substrate peptide, as required 
for more efficient catalytic activity. Further dissection of this mechanism and determination 
of whether these ligands are neutral allosteric modulators or negative allosteric modulators 
will depend upon definition of the structural changes in PRC2 upon binding of these 
compounds.21 Ultimately, these ligands recapitulate the centrality of EED to the catalytic 
output of PRC2.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(a) Structure of truncated Jarid2 peptide, Jarid2114–118K116me3. This native ligand served 
as the scaffold for subsequent ligand optimization studies and soluble competitor for the first 
generation combinatorial library. (b) The library screening scheme is presented. The OBOC 
library is incubated with His-tagged Kme reader proteins, excess protein is removed by 
rinsing. Protein G Dynabeads coated in anti-His antibody then enable magnetic enrichment 
of hit compounds while subsequent treatment with a soluble competitor elutes off lower 
affinity hits. (c) Jarid2114–118K116me3-derivative library was designed to probe ligand 
requirements at positions R1-R4. The native Jarid2 sequence was retained as the linker while 
also including methionine to enable hit cleavage via CNBr treatment. (d) High redundancy 
EED ligands. Both analogs were enriched via the magnetic enrichment assay with greater 
than two-fold redundancy.
Barnash et al. Page 17














Compound 1-derivative library was designed to improve EED ligand potency by exploring a 
narrower region of chemical space at R1-R4 while also probing the tolerance of the R5 
position to modification. The linker sequence provides distance between the library 
sequence and the solid support, and methionine was required for hit cleavage. Additionally, 
a lysine was included in the linker to promote proper display of the compounds on the bead 
surface39.
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a) Structure of compound 3. The sequence was derived from the residues found to occur 
most frequently at each position in the redundant hits of the second generation combinatorial 
library. b) Co-crystal structure of compound 3 bound to EED (PDB 5TTW). c) The aromatic 
cage (magenta) and the adjacent hydrophobic pocket (blue) occupied by Kme3 and proline, 
respectively. The backbone of the serine residue bridges these two pockets while the side 
chain points to solvent. d) Alignment of Jarid2110–120-K116me3 (dark grey) and compound 
3 (yellow) structures bound to EED demonstrating the constrained proline ring (compound 
3) replaces glutamine (Jarid2110–120-K116me3) and leucine (compound 3) contacts a 
broader surface than alanine (Jarid2110–120-K116me3).
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a) Structures of UNC5114, UNC5115, and UNC5197. b) In vitro PRC2 catalytic 
scintillation proximity assay results for highest potency EED binders and the negative 
control demonstrate this series of ligands inhibits PRC2 methyltransferase activity.
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Effect of H3K27me3 competition at varying concentrations on a) UNC5114, and b) 
UNC5115 inhibition of PRC2 catalytic activity. IC50 and Hill slope values for c) UNC5114 
and d) UNC5115. Experiments were carried out in triplicate.
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Chemiprecipitation of PRC2 core proteins. (A) Structure of C-terminally biotinylated 
derivative of UNC5114. (B) Western blot analysis indicating that UNC5114-biotin 
chemiprecipitates the intact PRC2 complex from PC-3 lystates with isolation of EED, Ezh2, 
and Suz12 (−). In the presence of soluble UNC5114, the ability of UNC5114-biotin to 
chemiprecipitate PRC2 is significantly reduced (+).
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Model for allosteric inhibition of PRC2 catalytic activity. EED aromatic cage ligands 
prevent binding of activating H3K27me3 peptides and may disrupt the stabilization of the 
SRM helix which in turn fails to engage and stabilize the SET-I helix.
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